Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lecanemab in Parkinson's Disease With Coexistent Alzheimer's Disease
NCT07544953Not yet recruiting
- Sponsor
- Yonsei University
- Start
- May 2026
- Primary completion
- Jun 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of lecanemab in Parkinson's disease (PD) (2 arms), sponsored by Yonsei University. Primary endpoint: Changes in amyloid deposition on amyloid imaging scans at 18 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
lecanemab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07544953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07544953.